Tumors' response to hormone therapy may be a biomarker for personalization of breast radiotherapy
How estrogen receptor-positive (ER+) breast cancer responds to hormone therapy may hold keys to understanding how it will respond to radiation therapy, and an experimental drug that increases the effectiveness of hormone therapy also overcomes radiation resistance in breast cancer, a study by UT Southwestern Medical Center researchers shows.
Source: news-medical.net